From Clinical Trial to Real-World Evidence: Everyday Practice with METex14 Inhibitors in NSCLC
This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).